This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
by Zacks Equity Research
Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.
Is Regeneron Pharmaceuticals (REGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (REGN) Outperforming Other Medical Stocks This Year?
Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60%
by Zacks Equity Research
Sanofi (SNY) and Regeneron (REGN) announce a 60% cut in the U.S. list price of their cholesterol lowering drug, Praluent to improve access and affordability of the product.
The Zacks Analyst Blog Highlights: Chevron, CSX, Regeneron, Capital One and Canadian National
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, CSX, Regeneron, Capital One and Canadian National
Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth
by Zacks Equity Research
Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.
Top Stock Reports for Chevron, CSX Corporation & Regeneron
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), CSX Corporation (CSX) and Regeneron (REGN).
Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea
by Zacks Equity Research
Regeneron's (REGN) earnings and sales surpass expectations in Q4 on solid Dupixent and Eylea sales.
Regeneron (REGN) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 20.21% and 12.83%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink
by Zacks Equity Research
Key highlights of the week were the fourth-quarter results by biotech bigwigs Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX) and Celgene (CELG).
Sanofi's Myeloma Candidate Meets Goal in Phase III Study
by Zacks Equity Research
Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.
Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
Strong Eylea and Dupixent sales are likely to propel better-than-expected results for Regeneron (REGN) when it reports fourth-quarter results.
Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion's key drug like Soliris should drive growth in the fourth quarter of 2018.
4 Healthcare Stocks Likely to Beat Estimates in Q4
by Zacks Equity Research
An aging population, prevalence of chronic health conditions and greater utilization of healthcare services should drive the industry's growth, partly offset by an increase in expenses.
Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study
by Zacks Equity Research
Eli Lilly (LLY) and Pfizer announce that their investigational pain candidate, tanezumab, achieves significant reduction in pain in osteoarthritis patients in second late-stage study.
Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio
5 Best Biotech Bets Likely to Outperform Estimates in Q4
by Zacks Equity Research
Let us take a look at five promising biotech stocks for the fourth quarter of 2018.
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
AbbVie (ABBV) is likely to beat earnings in fourth quarter. Impressive sales of its key drug, Humira and strong growth of Imbruvica and Mavyret are expected to drive fourth-quarter sales.
Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies
by Zacks Equity Research
Aerie's (AERI) Investigational New Drug Application for AR-1105 for the treatment of macular edema due to retinal vein occlusion is accepted by the FDA. The candidate will now enter clinical studies.
J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect
by Zacks Equity Research
J&J's (JNJ) Pharmaceuticals segment is likely to face difficult comparisons in fourth quarter.
Regeneron (REGN) Sails Steady on Label Expansion of Drugs
by Zacks Equity Research
Regeneron's (REGN) performance has been steady in the past six months even as the overall industry declines.
Can Regeneron (REGN) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus
by Zacks Equity Research
It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.
4 Biotechs That Are Potential Buyouts Post Celgene Deal
by Ekta Bagri
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.
Regeneron, Sanofi Restructure Immuno-Oncology Collaboration
by Zacks Equity Research
Regeneron (REGN) amends its existing agreement with Sanofi and selects two clinical-stage bispecific antibodies for the ongoing collaboration.